Sunscreen Drug Products for Over-the-Counter Human Use; Correction

---
identifier: "/us/fr/2019-07712"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Sunscreen Drug Products for Over-the-Counter Human Use; Correction"
title_number: 0
title_name: "Federal Register"
section_number: "2019-07712"
section_name: "Sunscreen Drug Products for Over-the-Counter Human Use; Correction"
positive_law: false
currency: "2019-04-18"
last_updated: "2019-04-18"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2019-07712"
document_type: "proposed_rule"
publication_date: "2019-04-18"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
cfr_references:
  - "21 CFR Part 201"
rin: "0910-AF43"
fr_citation: "84 FR 16220"
fr_volume: 84
docket_ids:
  - "Docket No. FDA-1978-N-0018 (formerly Docket No. FDA-1978-N-0038)"
comments_close_date: "2019-06-27"
fr_action: "Proposed rule; correction."
---


#  Sunscreen Drug Products for Over-the-Counter Human Use; Correction

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Proposed rule; correction.

**SUMMARY:**

The Food and Drug Administration (FDA) is correcting a proposed rule relating to the regulation of over-the-counter (OTC) sunscreen monograph products that appeared in the *Federal Register* of February 26, 2019. The document was published with formulas that were illegible. These corrections are being made to improve the accuracy of the proposed rule.

**DATES:**

Submit either electronic or written comments on the proposed rule by June 27, 2019.

**FOR FURTHER INFORMATION CONTACT:**

Kristen Hardin, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 5443, Silver Spring, MD 20993, 240-402-4246.

**SUPPLEMENTARY INFORMATION:**

In the *Federal Register* of February 26, 2019 (84 FR 6204), in FR Doc. 2019-03019, on pages 6267 through 6270, the following corrections are made:

1. On page 6267, in the first column, the formula under § 201.327(i)(2)(ii)(B) is corrected to read:

2. On page 6268, in the second column, the formula under § 201.327(i)(3)(ii)(C)( *2* ) is corrected to read:

3. On page 6268, in the second column, the formulas under § 201.327(i)(3)(ii)(D)( *2* )( *i* ) are corrected to read:

4. On page 6269, in the third column, the formula under § 201.327(i)(7)(i) is corrected to read:

5. On page 6269, in the third column, the formulas under § 201.327(i)(7)(ii) are corrected to read:

6. On page 6270, in the second column, the formula under § 201.327(j)(4)(ii) is corrected to read:

7. On page 6270, in the third column, the formulas under § 201.327(j)(5)(i) are corrected to read:

8. On page 6270, in the third column, the formula under § 201.327(j)(7) is corrected to read:

9. On page 6270, in the third column, the formula under § 201.327(j)(8) is corrected to read:

Elsewhere in this issue of the *Federal Register* , FDA is extending the comment period on the proposed rule.

Dated: April 12, 2019.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.